Page 'Sub' Navigation:
Page Path 'Breadcrumb':
About UsArdea, headquartered in San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. Ardea was formerly known as IntraBiotics Pharmaceuticals, Inc. and was incorporated in the State of Delaware in 1994.
In December 2006, we acquired intellectual property and other assets related to several classes of small-molecule therapeutics for the treatment of HIV and cancer from Valeant Research & Development, Inc., or Valeant. We have subsequently developed product candidates for the chronic management of hyperuricemia in gout patients through our own proprietary research and development efforts.
On June 19, 2012, Ardea was acquired by AstraZeneca PLC. Upon completion of the merger, Ardea became a wholly owned subsidiary of AstraZeneca. The total transaction value was approximately $1.26 billion. See Ardea's public filings with the Securities and Exchange Commission for more information.